Acrux Limited (ARUXF)
USD 0.04
(13.64%)
USD 0.04
(13.64%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -8.06 Million AUD | -187.11% |
| 2023 | -2.8 Million AUD | 79.9% |
| 2022 | -12.3 Million AUD | 21.04% |
| 2021 | -15.58 Million AUD | -37.09% |
| 2020 | -11.36 Million AUD | 9.51% |
| 2019 | -12.56 Million AUD | -166.41% |
| 2018 | -9.32 Million AUD | -120.68% |
| 2017 | 22.8 Million AUD | 9.67% |
| 2016 | 20.79 Million AUD | 13.4% |
| 2015 | 18.33 Million AUD | -61.67% |
| 2014 | 47.84 Million AUD | 339.51% |
| 2013 | 10.88 Million AUD | 200.88% |
| 2012 | 3.61 Million AUD | -95.67% |
| 2011 | 83.55 Million AUD | 67.49% |
| 2010 | 49.88 Million AUD | 600.12% |
| 2009 | -9.97 Million AUD | -41.09% |
| 2008 | -6.41 Million AUD | 24.19% |
| 2007 | -9.32 Million AUD | 20.85% |
| 2006 | -11.78 Million AUD | -109.54% |
| 2005 | -5.62 Million AUD | -42.36% |
| 2004 | -3.95 Million AUD | 30.77% |
| 2003 | -5.7 Million AUD | -51.21% |
| 2002 | -3.77 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 FY | - AUD | -225.99% |
| 2024 Q2 | -3.97 Million AUD | -318.79% |
| 2024 Q4 | -4.09 Million AUD | -3.1% |
| 2023 Q4 | 1.81 Million AUD | 139.37% |
| 2023 Q2 | -4.61 Million AUD | 22.36% |
| 2023 FY | - AUD | 79.9% |
| 2022 FY | - AUD | 21.04% |
| 2022 Q4 | -5.93 Million AUD | 6.75% |
| 2022 Q2 | -6.36 Million AUD | 20.19% |
| 2021 Q4 | -7.97 Million AUD | -4.89% |
| 2021 FY | - AUD | -37.09% |
| 2021 Q2 | -7.6 Million AUD | -33.86% |
| 2020 FY | - AUD | 9.51% |
| 2020 Q4 | -5.68 Million AUD | 0.05% |
| 2020 Q2 | -5.68 Million AUD | 17.39% |
| 2019 FY | - AUD | -166.41% |
| 2019 Q2 | -3.62 Million AUD | 23.91% |
| 2019 Q4 | -6.88 Million AUD | -89.93% |
| 2018 Q2 | -4.56 Million AUD | -372.21% |
| 2018 Q4 | -4.76 Million AUD | -4.34% |
| 2018 FY | - AUD | -120.68% |
| 2017 FY | - AUD | 9.67% |
| 2017 Q4 | 1.67 Million AUD | -82.42% |
| 2017 Q2 | 9.54 Million AUD | 81.91% |
| 2016 Q4 | 5.24 Million AUD | -61.93% |
| 2016 FY | - AUD | 13.4% |
| 2016 Q2 | 13.77 Million AUD | 119.87% |
| 2015 FY | - AUD | -61.67% |
| 2015 Q4 | 6.26 Million AUD | -41.35% |
| 2015 Q2 | 10.68 Million AUD | 66.69% |
| 2014 Q4 | 6.41 Million AUD | -83.49% |
| 2014 FY | - AUD | 339.51% |
| 2014 Q2 | 38.82 Million AUD | 390.47% |
| 2013 Q4 | 7.91 Million AUD | 269.86% |
| 2013 Q2 | 2.14 Million AUD | 0.0% |
| 2013 FY | - AUD | 200.88% |
| 2012 Q4 | - AUD | 0.0% |
| 2012 FY | - AUD | -95.67% |
| 2011 FY | - AUD | 67.49% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 Q4 | - AUD | 0.0% |
| 2010 FY | - AUD | 600.12% |
| 2009 FY | - AUD | -41.09% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2008 FY | - AUD | 24.19% |
| 2007 FY | - AUD | 20.85% |
| 2007 Q4 | - AUD | 0.0% |
| 2006 Q4 | - AUD | 0.0% |
| 2006 FY | - AUD | -109.54% |
| 2005 FY | - AUD | -42.36% |
| 2005 Q4 | - AUD | 0.0% |
| 2004 Q4 | - AUD | 0.0% |
| 2004 FY | - AUD | 30.77% |
| 2003 FY | - AUD | -51.21% |
| 2002 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.74 Million USD | -360.857% |
| Skye Bioscience, Inc. | -13.54 Million USD | 40.469% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 108.576% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 1629.104% |
| Qrons Inc. | -40.08 Thousand USD | -20021.753% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -2096.225% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -107.63% |
| BioStem Technologies, Inc. | -7.55 Million USD | -6.77% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -760.773% |
| CSL Limited | 4.78 Billion USD | 100.168% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 85.426% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 53.569% |
| Rebus Holdings, Inc. | -951 Thousand USD | -748.055% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1175.288% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 49.18% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 88.647% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -36.028% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -3272.36% |
| SQZ Biotechnologies Company | -64.14 Million USD | 87.426% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -204.979% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -425.048% |
| Mesoblast Limited | -62.38 Million USD | 87.073% |
| Marizyme, Inc. | -34.28 Million USD | 76.474% |
| Genus plc | 73.7 Million USD | 110.943% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -21.984% |
| Pharming Group N.V. | 9.87 Million USD | 181.654% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -442.217% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -127.375% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 8.06% |
| ContraFect Corporation | -64.99 Million USD | 87.592% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -78.185% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -475.328% |
| IMV Inc. | -35.52 Million USD | 77.297% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -247.058% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -1456.812% |
| ONE Bio Corp. | 13.61 Million USD | 159.245% |
| Accustem Sciences Inc. | -3.74 Million USD | -115.272% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 83.277% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -536.477% |
| Q BioMed Inc. | -617.62 Thousand USD | -1205.802% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 325.784% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -253.033% |
| Biomind Labs Inc. | -1.03 Million USD | -679.567% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 79.653% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -178.841% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -12.62% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 120043.486% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -32160.0% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -222.347% |
| GB Sciences, Inc. | -1.41 Million USD | -468.004% |
| Alpha Cognition Inc. | -9.7 Million USD | 16.904% |
| HST Global, Inc. | -5303.00 USD | -151983.726% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -292.076% |
| Halberd Corporation | -74.27 Thousand USD | -10757.712% |
| Enzolytics Inc. | -2.12 Million USD | -280.061% |
| Agentix Corp. | -1.37 Million USD | -487.933% |
| Resverlogix Corp. | -11.74 Million USD | 31.315% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -163.303% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 96.267% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 762.695% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 191.091% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -438.059% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 2228.845% |
| AVAX Technologies, Inc. | -6.11 Million USD | -31.94% |
| Zenith Capital Corp. | -8.6 Million USD | 6.286% |
| Genscript Biotech Corporation | -248.71 Million USD | 96.757% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -46194.702% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -229.66% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -4481.752% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -319.853% |
| Kadimastem Ltd | -2.62 Million USD | -207.311% |
| Helix BioMedix, Inc. | -1.04 Million USD | -670.803% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -4353.636% |
| LadRx Corporation | 412.28 Thousand USD | 2056.181% |
| Cell Source, Inc. | -4.27 Million USD | -88.764% |
| Regen BioPharma, Inc. | 1.46 Million USD | 650.153% |
| NovAccess Global Inc. | -1.03 Million USD | -679.38% |
| Affymax, Inc. | -14.29 Million USD | 43.582% |
| Itoco Inc. | -1.86 Million USD | -331.515% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -2024.493% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -622.67% |
| Mobile Lads Corp. | -2.24 Million USD | -259.858% |
| CytoDyn Inc. | -18.02 Million USD | 55.267% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -10105.115% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -65849.791% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -1560.565% |
| SYBLEU INC | -141.57 Thousand USD | -5596.788% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -659.409% |
| International Stem Cell Corporation | 202 Thousand USD | 4092.574% |
| Bioxytran, Inc. | -3.82 Million USD | -111.118% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -15221.049% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -227.588% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 77.515% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -17822.222% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -194.558% |
| Neutra Corp. | -181.24 Thousand USD | -4349.729% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 59.993% |
| PureTech Health plc | -11.62 Million USD | 30.636% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 59.99% |
| IXICO plc | -707 Thousand USD | -1040.736% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -4.945% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 83.318% |
| CSL Limited | 4.73 Billion USD | 100.17% |
| Cellectis S.A. | -92.63 Million USD | 91.294% |